Does the media prefer HSCS or MLSS?

In the previous week, HeartSciences had 10 more articles in the media than Milestone Scientific. MarketBeat recorded 12 mentions for HeartSciences and 2 mentions for Milestone Scientific. HeartSciences' average media sentiment score of 1.20 beat Milestone Scientific's score of 0.00 indicating that HeartSciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment HeartSciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Milestone Scientific 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend PETV or HSCS?

HeartSciences has a consensus target price of $8.00, indicating a potential upside of 186.74%. Given HeartSciences' stronger consensus rating and higher probable upside, analysts plainly believe HeartSciences is more favorable than PetVivo. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PetVivo 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 HeartSciences 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is PETV or HSCS more profitable?

HeartSciences has a net margin of 0.00% compared to PetVivo's net margin of -902.82%. HeartSciences' return on equity of -333.50% beat PetVivo's return on equity. Company Net Margins Return on Equity Return on Assets PetVivo -902.82% -4,813.07% -281.78% HeartSciences N/A -333.50% -140.18%

Does the media prefer PETV or HSCS?

In the previous week, HeartSciences had 8 more articles in the media than PetVivo. MarketBeat recorded 12 mentions for HeartSciences and 4 mentions for PetVivo. HeartSciences' average media sentiment score of 1.20 beat PetVivo's score of 0.40 indicating that HeartSciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PetVivo 0 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral HeartSciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to HSCS or PSTV?

In the previous week, HeartSciences had 7 more articles in the media than Plus Therapeutics. MarketBeat recorded 12 mentions for HeartSciences and 5 mentions for Plus Therapeutics. HeartSciences' average media sentiment score of 1.20 beat Plus Therapeutics' score of 0.47 indicating that HeartSciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment HeartSciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Plus Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer NMTC or HSCS?

In the previous week, HeartSciences had 9 more articles in the media than NeuroOne Medical Technologies. MarketBeat recorded 12 mentions for HeartSciences and 3 mentions for NeuroOne Medical Technologies. HeartSciences' average media sentiment score of 1.20 beat NeuroOne Medical Technologies' score of 0.24 indicating that HeartSciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NeuroOne Medical Technologies 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral HeartSciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend HSCS or POAI?

HeartSciences presently has a consensus target price of $8.00, suggesting a potential upside of 186.74%. Given HeartSciences' stronger consensus rating and higher probable upside, research analysts clearly believe HeartSciences is more favorable than Predictive Oncology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score HeartSciences 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Predictive Oncology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

HeartSciences (HSCS) Competitors

$2.79 0.00 (0.00%)

Closing price 07/2/2026 04:00 PM Eastern

Extended Trading

$2.76 -0.03 (-0.93%)

As of 06:14 AM Eastern

Compare

HSCS vs. MLSS, PETV, PSTV, NMTC, and POAI

Should you buy HeartSciences stock or one of its competitors? MarketBeat compares HeartSciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with HeartSciences include Milestone Scientific (MLSS), PetVivo (PETV), Plus Therapeutics (PSTV), NeuroOne Medical Technologies (NMTC), and Predictive Oncology (POAI). These companies are all part of the "medical equipment" industry.

How does HeartSciences compare to Milestone Scientific?

HeartSciences (NASDAQ:HSCS) and Milestone Scientific (NYSE:MLSS) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, valuation, analyst recommendations, media sentiment, earnings, risk and institutional ownership.

In the previous week, HeartSciences had 10 more articles in the media than Milestone Scientific. MarketBeat recorded 12 mentions for HeartSciences and 2 mentions for Milestone Scientific. HeartSciences' average media sentiment score of 1.20 beat Milestone Scientific's score of 0.00 indicating that HeartSciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
HeartSciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Milestone Scientific	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

HeartSciences has a beta of 1.78, indicating that its share price is 78% more volatile than the broader market. Comparatively, Milestone Scientific has a beta of 1.05, indicating that its share price is 5% more volatile than the broader market.

Milestone Scientific has higher revenue and earnings than HeartSciences. Milestone Scientific is trading at a lower price-to-earnings ratio than HeartSciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HeartSciences	N/A	N/A	-$8.77M	-$4.94	N/A
Milestone Scientific	$8.90M	3.40	-$6.93M	-$0.05	N/A

HeartSciences has a net margin of 0.00% compared to Milestone Scientific's net margin of -52.01%. Milestone Scientific's return on equity of -60.26% beat HeartSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
HeartSciences	N/A	-333.50%	-140.18%
Milestone Scientific	-52.01%	-60.26%	-40.23%

HeartSciences presently has a consensus target price of $8.00, suggesting a potential upside of 186.74%. Milestone Scientific has a consensus target price of $1.00, suggesting a potential upside of 192.14%. Given Milestone Scientific's stronger consensus rating and higher probable upside, analysts clearly believe Milestone Scientific is more favorable than HeartSciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
HeartSciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Milestone Scientific	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

17.2% of HeartSciences shares are held by institutional investors. Comparatively, 5.8% of Milestone Scientific shares are held by institutional investors. 4.9% of HeartSciences shares are held by company insiders. Comparatively, 9.2% of Milestone Scientific shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Milestone Scientific beats HeartSciences on 8 of the 14 factors compared between the two stocks.

How does HeartSciences compare to PetVivo?

PetVivo (NASDAQ:PETV) and HeartSciences (NASDAQ:HSCS) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, dividends, profitability, risk, valuation, media sentiment and analyst recommendations.

PetVivo has a beta of 1.23, suggesting that its stock price is 23% more volatile than the broader market. Comparatively, HeartSciences has a beta of 1.78, suggesting that its stock price is 78% more volatile than the broader market.

In the previous week, HeartSciences had 8 more articles in the media than PetVivo. MarketBeat recorded 12 mentions for HeartSciences and 4 mentions for PetVivo. HeartSciences' average media sentiment score of 1.20 beat PetVivo's score of 0.40 indicating that HeartSciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PetVivo	0 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
HeartSciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

HeartSciences has a consensus target price of $8.00, indicating a potential upside of 186.74%. Given HeartSciences' stronger consensus rating and higher probable upside, analysts plainly believe HeartSciences is more favorable than PetVivo.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PetVivo	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
HeartSciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

HeartSciences has a net margin of 0.00% compared to PetVivo's net margin of -902.82%. HeartSciences' return on equity of -333.50% beat PetVivo's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PetVivo	-902.82%	-4,813.07%	-281.78%
HeartSciences	N/A	-333.50%	-140.18%

HeartSciences has lower revenue, but higher earnings than PetVivo. PetVivo is trading at a lower price-to-earnings ratio than HeartSciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PetVivo	$1.05M	29.87	-$10.95M	-$0.38	N/A
HeartSciences	N/A	N/A	-$8.77M	-$4.94	N/A

24.5% of PetVivo shares are owned by institutional investors. Comparatively, 17.2% of HeartSciences shares are owned by institutional investors. 10.8% of PetVivo shares are owned by company insiders. Comparatively, 4.9% of HeartSciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

HeartSciences beats PetVivo on 11 of the 15 factors compared between the two stocks.

How does HeartSciences compare to Plus Therapeutics?

HeartSciences (NASDAQ:HSCS) and Plus Therapeutics (NASDAQ:PSTV) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, dividends, analyst recommendations, valuation, media sentiment, profitability and earnings.

HeartSciences has a net margin of 0.00% compared to Plus Therapeutics' net margin of -230.24%. Plus Therapeutics' return on equity of -198.48% beat HeartSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
HeartSciences	N/A	-333.50%	-140.18%
Plus Therapeutics	-230.24%	-198.48%	-73.13%

HeartSciences currently has a consensus price target of $8.00, suggesting a potential upside of 186.74%. Plus Therapeutics has a consensus price target of $56.40, suggesting a potential upside of 1,317.09%. Given Plus Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Plus Therapeutics is more favorable than HeartSciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
HeartSciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Plus Therapeutics	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

In the previous week, HeartSciences had 7 more articles in the media than Plus Therapeutics. MarketBeat recorded 12 mentions for HeartSciences and 5 mentions for Plus Therapeutics. HeartSciences' average media sentiment score of 1.20 beat Plus Therapeutics' score of 0.47 indicating that HeartSciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
HeartSciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Plus Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

HeartSciences has higher earnings, but lower revenue than Plus Therapeutics. Plus Therapeutics is trading at a lower price-to-earnings ratio than HeartSciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HeartSciences	N/A	N/A	-$8.77M	-$4.94	N/A
Plus Therapeutics	$5.21M	5.26	-$22.39M	-$2.30	N/A

HeartSciences has a beta of 1.78, suggesting that its share price is 78% more volatile than the broader market. Comparatively, Plus Therapeutics has a beta of 1.4, suggesting that its share price is 40% more volatile than the broader market.

17.2% of HeartSciences shares are held by institutional investors. Comparatively, 3.3% of Plus Therapeutics shares are held by institutional investors. 4.9% of HeartSciences shares are held by insiders. Comparatively, 2.5% of Plus Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

HeartSciences beats Plus Therapeutics on 8 of the 15 factors compared between the two stocks.

How does HeartSciences compare to NeuroOne Medical Technologies?

NeuroOne Medical Technologies (NASDAQ:NMTC) and HeartSciences (NASDAQ:HSCS) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, media sentiment, dividends, earnings, valuation and risk.

In the previous week, HeartSciences had 9 more articles in the media than NeuroOne Medical Technologies. MarketBeat recorded 12 mentions for HeartSciences and 3 mentions for NeuroOne Medical Technologies. HeartSciences' average media sentiment score of 1.20 beat NeuroOne Medical Technologies' score of 0.24 indicating that HeartSciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NeuroOne Medical Technologies	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
HeartSciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

16.1% of NeuroOne Medical Technologies shares are owned by institutional investors. Comparatively, 17.2% of HeartSciences shares are owned by institutional investors. 11.8% of NeuroOne Medical Technologies shares are owned by company insiders. Comparatively, 4.9% of HeartSciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

NeuroOne Medical Technologies has a beta of 0.54, meaning that its stock price is 46% less volatile than the broader market. Comparatively, HeartSciences has a beta of 1.78, meaning that its stock price is 78% more volatile than the broader market.

NeuroOne Medical Technologies has higher revenue and earnings than HeartSciences. NeuroOne Medical Technologies is trading at a lower price-to-earnings ratio than HeartSciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NeuroOne Medical Technologies	$12.10M	2.16	-$3.61M	-$0.85	N/A
HeartSciences	N/A	N/A	-$8.77M	-$4.94	N/A

NeuroOne Medical Technologies currently has a consensus price target of $11.67, indicating a potential upside of 288.89%. HeartSciences has a consensus price target of $8.00, indicating a potential upside of 186.74%. Given NeuroOne Medical Technologies' stronger consensus rating and higher probable upside, analysts clearly believe NeuroOne Medical Technologies is more favorable than HeartSciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NeuroOne Medical Technologies	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
HeartSciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

HeartSciences has a net margin of 0.00% compared to NeuroOne Medical Technologies' net margin of -68.35%. NeuroOne Medical Technologies' return on equity of -99.43% beat HeartSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NeuroOne Medical Technologies	-68.35%	-99.43%	-70.40%
HeartSciences	N/A	-333.50%	-140.18%

Summary

NeuroOne Medical Technologies beats HeartSciences on 9 of the 15 factors compared between the two stocks.

How does HeartSciences compare to Predictive Oncology?

HeartSciences (NASDAQ:HSCS) and Predictive Oncology (NASDAQ:POAI) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, earnings, dividends, profitability and analyst recommendations.

17.2% of HeartSciences shares are held by institutional investors. Comparatively, 9.0% of Predictive Oncology shares are held by institutional investors. 4.9% of HeartSciences shares are held by insiders. Comparatively, 1.2% of Predictive Oncology shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, HeartSciences had 12 more articles in the media than Predictive Oncology. MarketBeat recorded 12 mentions for HeartSciences and 0 mentions for Predictive Oncology. HeartSciences' average media sentiment score of 1.20 beat Predictive Oncology's score of 0.00 indicating that HeartSciences is being referred to more favorably in the media.

Company	Overall Sentiment
HeartSciences	Positive
Predictive Oncology	Neutral

HeartSciences has a beta of 1.78, indicating that its share price is 78% more volatile than the broader market. Comparatively, Predictive Oncology has a beta of 1.35, indicating that its share price is 35% more volatile than the broader market.

HeartSciences presently has a consensus target price of $8.00, suggesting a potential upside of 186.74%. Given HeartSciences' stronger consensus rating and higher probable upside, research analysts clearly believe HeartSciences is more favorable than Predictive Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
HeartSciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Predictive Oncology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

HeartSciences has higher earnings, but lower revenue than Predictive Oncology. HeartSciences is trading at a lower price-to-earnings ratio than Predictive Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HeartSciences	N/A	N/A	-$8.77M	-$4.94	N/A
Predictive Oncology	$1.66M	14.44	-$12.66M	-$13.50	N/A

HeartSciences has a net margin of 0.00% compared to Predictive Oncology's net margin of -5,065.23%. HeartSciences' return on equity of -333.50% beat Predictive Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
HeartSciences	N/A	-333.50%	-140.18%
Predictive Oncology	-5,065.23%	-732.73%	-235.55%

Summary

HeartSciences beats Predictive Oncology on 13 of the 15 factors compared between the two stocks.

Get HeartSciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HSCS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

HSCS vs. The Competition

Export

Metric	HeartSciences	MEDICAL INFO SYS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$8.87M	$1.83B	$6.98B	$12.46B
Dividend Yield	N/A	N/A	2.66%	6.52%
P/E Ratio	-0.56	81.75	27.78	24.70
Price / Sales	N/A	7.53	534.41	98.72
Price / Cash	N/A	26.08	29.65	49.23
Price / Book	15.50	5.75	11.04	6.49
Net Income	-$8.77M	-$54.76M	$3.57B	$336.25M
7 Day Performance	1.45%	2.05%	1.15%	0.35%
1 Month Performance	43.81%	2.93%	6.08%	3.91%
1 Year Performance	-24.08%	-0.07%	33.32%	23.88%

HeartSciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
HSCS HeartSciences	2.6295 of 5 stars	$2.79 flat	$8.00 +186.7%	-24.1%	$8.87M	N/A	N/A	10	Trending News Analyst Revision
MLSS Milestone Scientific	1.2657 of 5 stars	$0.35 +9.2%	$1.00 +185.3%	-48.9%	$31.00M	$8.90M	N/A	30	Gap Up
PETV PetVivo	N/A	$0.84 flat	N/A	+6.6%	$30.59M	$1.05M	N/A	20	Gap Down
PSTV Plus Therapeutics	2.2705 of 5 stars	$4.16 -4.8%	$56.40 +1,255.8%	-46.2%	$30.08M	$5.21M	N/A	20	Gap Up
NMTC NeuroOne Medical Technologies	2.5363 of 5 stars	$3.00 -1.3%	$11.67 +288.9%	-30.1%	$26.46M	$12.10M	N/A	20	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:HSCS) was last updated on 7/6/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

HeartSciences (HSCS) Competitors

HSCS vs. MLSS, PETV, PSTV, NMTC, and POAI

How does HeartSciences compare to Milestone Scientific?

Summary

How does HeartSciences compare to PetVivo?

Summary

How does HeartSciences compare to Plus Therapeutics?

Summary

How does HeartSciences compare to NeuroOne Medical Technologies?

Summary

How does HeartSciences compare to Predictive Oncology?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HSCS vs. The Competition

HeartSciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

HeartSciences (HSCS) Competitors

HSCS vs. MLSS, PETV, PSTV, NMTC, and POAI

How does HeartSciences compare to Milestone Scientific?

Does the media prefer HSCS or MLSS?

Which has more risk & volatility, HSCS or MLSS?

Which has better earnings and valuation, HSCS or MLSS?

Is HSCS or MLSS more profitable?

Do analysts recommend HSCS or MLSS?

Do institutionals and insiders have more ownership in HSCS or MLSS?

Summary

How does HeartSciences compare to PetVivo?

Which has more risk and volatility, PETV or HSCS?

Does the media prefer PETV or HSCS?

Do analysts recommend PETV or HSCS?

Is PETV or HSCS more profitable?

Which has higher earnings and valuation, PETV or HSCS?

Do insiders & institutionals believe in PETV or HSCS?

Summary

How does HeartSciences compare to Plus Therapeutics?

Is HSCS or PSTV more profitable?

Do analysts rate HSCS or PSTV?

Does the media refer more to HSCS or PSTV?

Which has preferable valuation & earnings, HSCS or PSTV?

Which has more volatility & risk, HSCS or PSTV?

Do insiders and institutionals believe in HSCS or PSTV?

Summary

How does HeartSciences compare to NeuroOne Medical Technologies?

Does the media prefer NMTC or HSCS?

Do insiders and institutionals believe in NMTC or HSCS?

Which has more risk & volatility, NMTC or HSCS?

Which has higher valuation and earnings, NMTC or HSCS?

Do analysts recommend NMTC or HSCS?

Is NMTC or HSCS more profitable?

Summary

How does HeartSciences compare to Predictive Oncology?

Do insiders & institutionals hold more shares of HSCS or POAI?

Does the media refer more to HSCS or POAI?

Which has more risk and volatility, HSCS or POAI?

Do analysts recommend HSCS or POAI?

Which has better earnings & valuation, HSCS or POAI?

Is HSCS or POAI more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HSCS vs. The Competition

HeartSciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools